Metabolic/Weight

Eloralintide

Research Reagent · Laboratory Use Only

Quick Answer

What does research show about eloralintide for weight loss?

Eloralintide (LY3841136) is Eli Lilly's selective amylin receptor agonist peptide, a GLP-1-independent mechanism for obesity treatment. In a Phase 2 trial published in the Lancet (December 2025), eloralintide produced dose-dependent weight loss of 9-20% at 48 weeks versus 0.4% with placebo. Lilly has since started multiple Phase 3 trials, including studies in type 2 diabetes, obstructive sleep apnea, combination with macupatide, and as an add-on for patients whose weight loss plateaus on existing incretin therapy.

PMID41207310↗DOI10.1016/S0140-6736(25)02155-5↗⟳ Reconstitution Calculator
Scientific AbstractPMID 41207310 · 2025

Eloralintide (LY3841136) is a selective amylin receptor agonist peptide developed by Eli Lilly, administered by once-weekly subcutaneous injection, that acts independently of the GLP-1 pathway used by tirzepatide and semaglutide. In a Phase 2, double-blind, randomized, placebo-controlled trial (Lancet, December 2025; PMID 41207310; NCT06230523), 263 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes, were randomized across six eloralintide dose/titration arms (1 mg, 3 mg, 6 mg, 9 mg, 6-9 mg, 3-9 mg) or placebo for 48 weeks. 4% with placebo, without a clear plateau at the higher doses.

The most common adverse events were nausea and fatigue, generally dose-dependent. Based on these results, Lilly advanced eloralintide into a Phase 3 program in late 2025/2026, including trials in type 2 diabetes (NCT07282600), obstructive sleep apnea with obesity (NCT07369011), combination with the GIP-agonist macupatide (NCT07215559), and as an add-on for patients with persistent obesity/overweight on an existing weekly incretin (NCT07392190, ENLIGHTEN-6).

Source:10.1016/S0140-6736(25)02155-5
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is Eloralintide?

Eloralintide (development code LY3841136) is a selective amylin receptor agonist peptide developed by Eli Lilly for obesity and weight management. Unlike GLP-1-pathway drugs (semaglutide, tirzepatide, retatrutide), eloralintide works through amylin receptor signaling alone, positioning it as both a potential monotherapy and an add-on for patients whose weight loss has plateaued on incretin-class therapy.

Mechanism of Action

Eloralintide selectively activates the amylin receptor, mimicking the satiety-signaling effects of endogenous amylin (co-secreted with insulin) without engaging GLP-1 or GIP receptors. This distinct mechanism reduces food intake and promotes weight loss, and may combine additively with incretin-pathway drugs rather than competing with them.

Observed Clinical Results

  • Phase 2 trial (Lancet, December 2025; PMID 41207310; NCT06230523): 263 participants; 48-week mean bodyweight reduction of 9–20% across dose arms vs 0.4% with placebo; most common adverse events were nausea and fatigue.
  • Phase 3 NCT07282600: Adults with obesity/overweight and type 2 diabetes; recruiting.
  • Phase 3 NCT07369011: Adults with obstructive sleep apnea and obesity/overweight; recruiting.
  • Phase 3 NCT07215559: Macupatide (LY3532226) and eloralintide, alone or in combination, in adults with obesity/overweight and type 2 diabetes.
  • Phase 3 NCT07392190 (ENLIGHTEN-6): Add-on to a weekly incretin in adults with persistent obesity/overweight, with and without type 2 diabetes.

Regulatory Status

Investigational — no regulatory approval as of July 2026. Multiple Phase 3 trials recruiting/ongoing since late 2025. Not eligible for 503A compounding as an investigational biologic peptide.

Clinical Research Parameters
5 trials1 human study

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Registered Clinical Trials
ClinicalTrials.gov ↗
NCT06230523 ↗
COMPLETEDPhase IIn=263

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

48-week, multicentre, double-blind, randomised, placebo-controlled Phase 2 trial evaluating once-weekly subcutaneous eloralintide (1 mg, 3 mg, 6 mg, 9 mg, or dose-escalated 6-9 mg / 3-9 mg) versus placebo in 263 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes. Mean bodyweight reduction at 48 weeks ranged from 9% (1 mg) to 20% (9 mg and 6-9 mg) versus 0.4% with placebo. Most common adverse events were nausea and fatigue, generally dose-dependent. Published in the Lancet, December 2025.

Study Interventions
Eloralintide (LY3841136), Placebo
Primary Endpoints
Percent change in bodyweight from baseline at 48 weeks
Study Period
2024-02 → 2025-08
NCT07282600 ↗
RECRUITINGPhase III

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Phase 3 randomised, double-blind, placebo-controlled study of once-weekly eloralintide in adults with obesity or overweight and type 2 diabetes. Part of Lilly's Phase 3 program launched following positive Phase 2 results.

Study Interventions
Eloralintide (LY3841136), Placebo
Primary Endpoints
Percent change in bodyweight from baseline
Study Period
2026
NCT07369011 ↗
RECRUITINGPhase III

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Phase 3 study evaluating the efficacy and safety of eloralintide in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight.

Study Interventions
Eloralintide (LY3841136), Placebo
Primary Endpoints
Apnea-hypopnea index change from baseline; Percent change in bodyweight from baseline
Study Period
2026
NCT07215559 ↗
RECRUITINGPhase II

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Study evaluating the GIP-agonist macupatide and the amylin agonist eloralintide, alone and in combination, for weight reduction in adults with obesity/overweight and type 2 diabetes.

Study Interventions
Macupatide (LY3532226), Eloralintide (LY3841136), Placebo
Primary Endpoints
Percent change in bodyweight from baseline
Study Period
2026
NCT07392190 ↗
RECRUITINGPhase III

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (ENLIGHTEN-6)

Phase 3 randomised, double-blind, placebo-controlled study investigating whether adding once-weekly eloralintide to an existing weekly incretin therapy (e.g., semaglutide, tirzepatide) further reduces bodyweight in adults with persistent obesity or overweight, with and without type 2 diabetes.

Study Interventions
Eloralintide (LY3841136) add-on, Placebo add-on
Primary Endpoints
Percent change in bodyweight from baseline
Study Period
2026-06
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. Eloralintide is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 41207310) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Metabolic/Weight Research Compounds

Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the management of ob…
→
Tirzepatide
INTRODUCTION: Tirzepatide has been associated with significant reductions in body weight i…
→
Retatrutide
OBJECTIVES: Functional co- and tri-agonists at the receptors for GLP-1, GIP and glucagon e…
→
Liraglutide
PURPOSE: To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 R…
→
View all Metabolic/Weight compounds →